Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
drugs
7
×
life sciences
7
×
national blog main
clinical trials
brexit
europe
europe blog main
falsified medicines
fda
innovation
labeling
mhra
regulations
uk
amgen
boston blog main
national
new york blog main
achaogen
adams street partners
alirocumab
alnylam pharmaceuticals
antibiotics
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boston
boston top stories
calcitonin gene-related peptide
chronic migraine
crispr
cystic fibrosis
cystic fibrosis foundation
deals
drug resistance
eli lilly
episodic migraine
evercore isi
evolocumab
gilead sciences
What
medicines
7
×
brexit
charting
choppy
course
drug
dynamic
end
period
plans
post
regulation
regulatory
reveals
transition
uk
new
pharmaceuticals
alnylam
announced
approval
approved
bacteria
based
biopharma
business
cf
cholesterol
class
company
crisis
cystic
data
decision
developed
developer
disease
eli
evidence
exited
Language
unset
unknown
Current search:
medicines
×
biotech
×
" life sciences "
×
drugs
×
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines